Wolfgang A Tomé1, C Wesley Hodge2, Minesh P Mehta3, Søren M Bentzen1. 1. Departments of Human Oncology and Medical Physics, School of Medicine and Public Health, University of Wisconsin, Madison, USA. 2. Department of Radiation Oncology, Robert Boissoneault Oncology Institute, Ocala, Florida, USA. 3. Department of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Abstract
PURPOSE/ OBJECTIVES: Late complications of SBRT include radiation related rib fractures. We estimate the incidence of rib fracturesas a function of maximum absorbed rib dose after stereotactic body radiotherapy (SBRT) for early stage lung cancer. MATERIALS/ METHODS: Of 23 patients treated with image guided SBRT (60 Gy in 5 fractions) between 2003 and 2006, 4 developed pathological rib fractures near the SBRT planning target volume (PTV). Both planned maximum dose and maximum Fraction-size equivalent dose (FED) to the combined rib volume lying within the prescription isodose volume was determined and a probit dose response model was fitted to the observed rib fracture data for each. RESULTS: 17 patients were evaluated, all with a minimum of 15 months follow-up. Median followup was 43 months (range 15-60 months). The median time to rib fracture was 26.5 months (range 15-34 months). The maximum rib dose ranged from 23.8-74.7 Gy (median 57.8 Gy) in 5 fractions. Dose was a significant predictor of rib fracture (p=0.02), with a D50 (123FED50) estimate of 66.71 Gy (73.52 Gy). The steepness of the dose-response curve was quantified by the m and γ50 value, estimated at m = 0.1663 and γ50 = 2.39 for the maximum dose probit dose response model and at m = 0.2747 and γ50 = 1.45 for the maximum 123FED50 probit dose response model. CONCLUSIONS: Maximum rib dose should be carefully considered in SBRT with appropriate risk counseling of patients whose maximum rib dose exceeds a dose of 50 Gy in 5 fractions or a maximum 123FED50 of 43.1 Gy, estimated to be associated with a 6.6 % risk of rib fractures. Hence, the inclusion of ribs as an "organ at risk" in intensity modulated radiotherapy (IMRT) planning should be considered as a way to reduce the likelihood of rib fractures.
PURPOSE/ OBJECTIVES: Late complications of SBRT include radiation related rib fractures. We estimate the incidence of rib fracturesas a function of maximum absorbed rib dose after stereotactic body radiotherapy (SBRT) for early stage lung cancer. MATERIALS/ METHODS: Of 23 patients treated with image guided SBRT (60 Gy in 5 fractions) between 2003 and 2006, 4 developed pathological rib fractures near the SBRT planning target volume (PTV). Both planned maximum dose and maximum Fraction-size equivalent dose (FED) to the combined rib volume lying within the prescription isodose volume was determined and a probit dose response model was fitted to the observed rib fracture data for each. RESULTS: 17 patients were evaluated, all with a minimum of 15 months follow-up. Median followup was 43 months (range 15-60 months). The median time to rib fracture was 26.5 months (range 15-34 months). The maximum rib dose ranged from 23.8-74.7 Gy (median 57.8 Gy) in 5 fractions. Dose was a significant predictor of rib fracture (p=0.02), with a D50 (123FED50) estimate of 66.71 Gy (73.52 Gy). The steepness of the dose-response curve was quantified by the m and γ50 value, estimated at m = 0.1663 and γ50 = 2.39 for the maximum dose probit dose response model and at m = 0.2747 and γ50 = 1.45 for the maximum 123FED50 probit dose response model. CONCLUSIONS: Maximum rib dose should be carefully considered in SBRT with appropriate risk counseling of patients whose maximum rib dose exceeds a dose of 50 Gy in 5 fractions or a maximum 123FED50 of 43.1 Gy, estimated to be associated with a 6.6 % risk of rib fractures. Hence, the inclusion of ribs as an "organ at risk" in intensity modulated radiotherapy (IMRT) planning should be considered as a way to reduce the likelihood of rib fractures.
Entities:
Keywords:
Cancer; Lung; NTCP; Radiotherapy; Rib fractures; Stereotactic body radiotherapy
Authors: Wes Hodge; Wolfgang A Tomé; Hazim A Jaradat; Nigel P Orton; Deepak Khuntia; Anne Traynor; Tracey Weigel; Minesh P Mehta Journal: Acta Oncol Date: 2006 Impact factor: 4.089
Authors: P Giraud; M Antoine; A Larrouy; B Milleron; P Callard; Y De Rycke; M F Carette; J C Rosenwald; J M Cosset; M Housset; E Touboul Journal: Int J Radiat Oncol Biol Phys Date: 2000-11-01 Impact factor: 7.038
Authors: Frank J Lagerwaard; Cornelis J A Haasbeek; Egbert F Smit; Ben J Slotman; S Senan Journal: Int J Radiat Oncol Biol Phys Date: 2007-12-31 Impact factor: 7.038
Authors: Neal E Dunlap; Jing Cai; Gregory B Biedermann; Wensha Yang; Stanley H Benedict; Ke Sheng; Tracey E Schefter; Brian D Kavanagh; James M Larner Journal: Int J Radiat Oncol Biol Phys Date: 2009-05-08 Impact factor: 7.038